--- title: Intra-articular Tenoxicam Versus Triamcinolone Acetonide in Knee Osteoarthritis Management nct_id: NCT07194135 overall_status: COMPLETED phase: NA sponsor: Benha University study_type: INTERVENTIONAL primary_condition: Osteoarthritis, Knee countries: Egypt canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07194135.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07194135" ct_last_update_post_date: 2025-09-26 last_seen_at: "2026-05-12T06:00:39.185Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Intra-articular Tenoxicam Versus Triamcinolone Acetonide in Knee Osteoarthritis Management **Official Title:** Comparison of Intra-articular Tenoxicam and Triamcinolone Acetonide in the Management of Knee Osteoarthritis: A Randomized Prospective Study **NCT ID:** [NCT07194135](https://clinicaltrials.gov/study/NCT07194135) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 100 - **Lead Sponsor:** Benha University - **Conditions:** Osteoarthritis, Knee - **Start Date:** 2024-11-03 - **Completion Date:** 2025-04-30 - **CT.gov Last Update:** 2025-09-26 ## Brief Summary Knee osteoarthritis is a very common joint condition that leads to pain, stiffness, and difficulty with daily activities, particularly in middle-aged and older adults. Many patients do not get adequate relief from oral pain medications, non-steroidal anti-inflammatory drugs, or physical therapy. Because of this, injections directly into the knee joint are often used. Corticosteroid medicines, such as triamcinolone acetonide, are among the most frequently used intra-articular injections. They provide strong and rapid anti-inflammatory effects, but their benefits often wear off after only a few weeks. In addition, corticosteroids may cause unwanted systemic effects such as temporary increases in blood sugar, which can be especially concerning for patients with diabetes. Non-steroidal anti-inflammatory drugs are another group of medicines that can relieve pain and inflammation. Tenoxicam is a long-acting medicine from this group. When given directly into the knee joint, tenoxicam may provide local pain relief for a longer duration, while reducing the amount of drug that circulates in the body. This may lower the risk of side effects compared with oral treatment or repeated corticosteroid injections. This clinical study was designed to compare the effects of a single intra-articular injection of tenoxicam with a single intra-articular injection of triamcinolone acetonide in patients who have symptomatic knee osteoarthritis. The primary aim was to determine which treatment provides better improvement in knee pain, measured using a visual analog scale. Secondary aims included evaluating knee function using the Western Ontario and McMaster Universities Osteoarthritis Index, monitoring blood sugar control using glycated hemoglobin testing, and assessing the safety of each treatment by recording any local or general adverse events. ## Eligibility - **Minimum age:** 45 Years - **Maximum age:** 75 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Adults aged 45 to 75 years * Radiographically confirmed knee osteoarthritis (Kellgren-Lawrence grade II-III) * Persistent knee pain for at least 3 months despite oral non-steroidal anti-inflammatory drugs * Ability to provide informed consent Exclusion Criteria: * Prior intra-articular injection within the past 6 months * Inflammatory arthritis (e.g., rheumatoid arthritis, gout) * Advanced knee osteoarthritis (Kellgren-Lawrence grade IV) * Active joint or systemic infection * Bleeding disorder or anticoagulant use contraindicating injection * Uncontrolled diabetes mellitus * Known hypersensitivity to tenoxicam or triamcinolone acetonide ``` ## Arms - **Tenoxicam Injection** (EXPERIMENTAL) — Participants received a single intra-articular injection of tenoxicam 20 milligrams, administered aseptically through an anterolateral approach to the knee joint. - **Triamcinolone Acetonide Injection** (ACTIVE_COMPARATOR) — Participants received a single intra-articular injection of triamcinolone acetonide 40 milligrams, administered aseptically through an anterolateral approach to the knee joint. ## Interventions - **Tenoxicam** (DRUG) — Intra-articular administration of tenoxicam, 20 milligrams as a single injection, delivered through an anterolateral approach under aseptic technique. - **Triamcinolone Acetonide** (DRUG) — Intra-articular administration of triamcinolone acetonide, 40 milligrams as a single injection, delivered through an anterolateral approach under aseptic technique. ## Primary Outcomes - **Change in Knee Pain Intensity Measured by Visual Analog Scale** _(time frame: Baseline, 2 weeks, 6 weeks, and 12 weeks after injection)_ — Pain intensity in the affected knee was assessed using a visual analog scale (0 to 100 millimeters), where 0 represents no pain and 100 represents the worst imaginable pain. The outcome was defined as the change from baseline score to follow-up assessments. ## Secondary Outcomes - **Change in Knee Function Measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)** _(time frame: Baseline, 2 weeks, 6 weeks, and 12 weeks after injection)_ - **Change in Glycemic Control Measured by Glycated Hemoglobin (HbA1c)** _(time frame: Baseline and 1 month after injection)_ ## Locations (1) - Benha University Hospitals, Department of Orthopedics and Rheumatology, Banhā, Qalyubia Governorate, Egypt ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.benha university hospitals, department of orthopedics and rheumatology|banhā|qalyubia governorate|egypt` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT07194135.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT07194135* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*